SPY310.52+2.16 0.70%
DIA257.31-0.56 -0.22%
IXIC10,154.63+95.86 0.95%

Baird Initiates Coverage On Vir Biotechnology with Neutral Rating, Announces $17 Price Target

Baird initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Neutral rating and a $17 price target.

Benzinga · -

Baird initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Neutral rating and a $17 price target.